Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.62 |
| ▸ | HTR2C | P28335 | 6/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL3529128 | 0.94 | HTR2A (0.56) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL31707510 | 0.85 | HTR2A (0.58) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL4980231 | 0.84 | RAB9A (0.74) | HRH3RAB9ASMN1; SMN2NPC1MCHR1 | |
| SCHEMBL4975779 | 0.81 | DRD4 (0.59) | HRH3RAB9ASMN1; SMN2NPC1MCHR1 | |
| SCHEMBL4984077 | 0.81 | NPC1 (0.55) | HTR2CHRH3RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4978994 | 0.80 | SMN1; SMN2 (0.72) | HRH3RAB9ASMN1; SMN2NPC1MCHR1 | |
| SCHEMBL31473510 | 0.80 | HTR2A (0.71) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL8219973 | 0.80 | MAPT (0.64) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL14263119 | 0.80 | RAB9A (0.54) | HRH3RAB9ASMN1; SMN2NPC1MCHR1 | |
| SCHEMBL4982545 | 0.79 | MCHR1 (0.66) | HTR2AHRH3RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061176-A1 | CYCLOALKANE-SUBSTITUTED AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2025-03-27 | — | — | WO | disclosed |
| CN-119661404-A | Cycloalkane substituted amine derivative, preparation method and application thereof | 上海科技大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3325444-B1 | METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C | ACADIA PHARM INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3828170-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | Livzon New North River Pharmaceutical Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-10934257-B2 | Method for preparing pimavanserin and tartrate thereof by using triphosgene | LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20200369612-A1 | Method for Safely Preparing Pimavanserin and Tartrate Thereof by Using Triphosgene | LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| WO-2020020064-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | 丽珠集团新北江制药股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
| EP-2200610-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | Acadia Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-2173343-A1 | USE OF PIMAVANSERIN IN THE TREATMENT OF PARKINSON AND SYMPTOMS THEREOF | Acadia Pharmaceuticals Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009039460-A2 | CO-ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008144665-A1 | USE OF PIMAVANSERIN IN THE TREATMENT OF PARKINSON AND SYMPTOMS THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369612-A1 | Method for Safely Preparing Pimavanserin and Tartrate Thereof by Using Triphosgene | PNP, PIM1, TYMP | HTR2A 1753/4885HTR2C 2737/4885HRH3 3416/4885 |
| US-10934257-B2 | Method for preparing pimavanserin and tartrate thereof by using triphosgene | PNP, TYMP, PIM1 | HTR2A 1585/4885HTR2C 2514/4885HRH3 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.